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COELIAC DISEASE
Mutagenesis of the catalytic triad of tissue transglutaminase
abrogates coeliac disease serum IgA autoantibody binding
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Background and aims: Tissue transglutaminase (tTG) is an autoantigen in coeliac disease and the related
disorder, dermatitis herpetiformis. The detection of autoantibodies directed against tTG is a highly specific
marker of coeliac disease; however, it is unclear if there is a role for these autoantibodies in the disease
process. The aim of this study was to investigate whether the catalytic triad of tTG is targeted by coeliac
disease autoantibodies.
Methods: A full-length wild-type recombinant tTG and a novel site-directed mutagenic variant lacking the
catalytic triad were produced in Escherichia coli. Serum samples from 61 biopsy-proven coeliac disease and
10 dermatitis herpetiformis patients were tested for their recognition of both antigens in enzyme-linked
immunosorbent assay.
Results: Although IgA autoantibodies from sera of patients with coeliac disease and dermatitis herpetiformis
bound wild-type tTG well, a dramatic decrease in binding to the mutant tTG was observed with a mean reduction
of 79% in coeliac disease and 58% in dermatitis herpetiformis samples. IgG anti-tTG antibodies did not show a
similar pattern of reduction, with no overall difference in recognition of the wild-type or mutant tTGs.
Conclusions: These results suggest that the IgA anti-tTG response in coeliac disease and dermatitis
herpetiformis is focused on the region of tTG responsible for its transamidation and deamidation reactions,
whereas the IgG response may target other regions of the enzyme.
T
issue transglutaminase (tTG) is a member of a family of
enzymes responsible for the post-translational modification
of proteins by the introduction of e-(c-glutaminyl)lysine
cross-links.1 As well as transamidation reactions, other roles for
tTG have been suggested in apoptosis,2 extracellular matrix
interactions,3–5 wound healing,6 CD8+ T cell transendothelial
migration,7 GTP hydrolysis8 and signal transduction.9 The
catalytic triad of tTG (Cys277, His335 & Asp358) performs the
cross-linking reaction by attaching a target glutamine to an
available lysine in a Ca2+-dependent manner. In the absence of
an available lysine residue and in the presence of water, tTG can
deamidate its target glutamine residue.
In 1997 Dieterich and colleagues discovered that tTG is the
predominant autoantigen in coeliac disease, a malabsorptive
disorder of the small intestine caused by wheat gluten
ingestion.10 Coeliac disease affects approximately 1 in 200
Europeans11 and is characterised by damage to the villous
architecture of the upper small intestine with considerable
mononuclear cell infiltration. Coeliac disease has a strong
genetic component, with most patients expressing the DQ2
heterodimer.12 In 2002 Vader and colleagues discovered that
deamidation of specific glutamine residues in wheat gliadin
peptides by tTG significantly enhanced their binding to DQ2
and hence increased their immunogenicity.13 The mechanisms
underlying the autoimmune response directed against tTG in
coeliac disease are unknown, but the formation of gliadin-tTG
complexes by transglutaminase activity seems to be required for
the process.10 The detection of IgA antibodies directed against
tTG is a highly sensitive serological test for diagnosing coeliac
disease.14 However, their role, if any, in the disease process
remains unknown. Dermatitis herpetiformis is a related gluten-
sensitive enteropathy that is characterised by IgA deposits at
the dermoepidermal junction of the skin.15 It is also associated
with IgA anti-tTG reactivity, but in a lower percentage of
cases.16 Epidermal transglutaminase has been established as the
predominant autoantigen in dermatitis herpetiformis.17
In one recent study investigating autoantibody binding to
truncated tTG protein fragments, Sblattero et al. (2002) found
evidence for a conformation-dependant epitope within the core
region of tTG (amino acids 140 to 376), the domain of the
enzyme in which the catalytic triad is located.18 The presence of
calcium in enzyme-linked immunosorbent assay (ELISA) coat-
ing buffers has been shown to induce a conformational change
revealing the catalytic triad19 and to increase autoantibody
binding.20 Because the catalytic triad is a site of interaction for
tTG with gliadin peptides, and possibly a site for intermolecular
epitope spreading, this study was designed to establish whether
the catalytic triad of tTG is targeted by coeliac disease
autoantibodies. To this end, full-length tTG and a novel site-
directed mutagenic tTG lacking the Cys–His–Asp catalytic triad
were produced and tested as antigen in ELISAs with cohorts of
coeliac disease and dermatitis herpetiformis sera to determine
the importance of the catalytic core in tTG–autoantibody
interactions.
MATERIALS AND METHODS
Serum samples
Seventy-six serum samples from 61 patients (46 females, 15
males; age 15 to 76 years, median = 50) with coeliac disease
were used to characterise anti-tTG binding. Diagnosis was
based upon histology of duodenal biopsy as well as positivity
for anti-tTG and anti-endomysial antibodies. Sera from 10
dermatitis herpetiformis patients (3 females, 7 males; age 19 to
64 years, median = 53) were also included in the study. Forty-
nine sera (29 females, 20 males; age 17 to 84, median = 53)
from individuals with normal intestinal biopsy and negative
anti-tTG serology as determined using the CelikeyH ELISA
Abbreviations: tTG, tissue transglutaminase; IPTG, Isopropyl b-D-1-
thiogalactopyranoside; rpm, revolutions per minute; PBS, phosphate
buffered saline
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system (Pharmacia Diagnostics) were used to establish cut-off
points for ELISAs.
Polymerase chain reaction amplification, cloning and
site-directed mutagenesis of tTG constructs
Total RNA was extracted from peripheral blood mononuclear
cells by standard methods. cDNA was generated by a 60 minute
reverse transcription reaction using AMV reverse transcriptase
(Promega). The full-length tTG sequence was amplified by
polymerase chain reaction (PCR) using the following condi-
tions and primers: 40 cycles of 95 C˚ 30 s, 55 C˚ 30 s and 72 C˚
2 min. (Fwd: 59-GATCGAATTCATGGCCGAGGAGCTGGTCTT
AG-39 Rev: 59-GATCCTCGAGTTAGGCGGGGCCAATGATGAC-
39). The tTG PCR product was ligated to the pGEX-4T-1 vector
(Amersham Biosciences) by EcoRI and XhoI restriction sites.
Site-directed mutagenesis replaced the Cys–His–Asp catalytic
triad with alanine residues using the QuickchangeH system
(Stratagene). Primers used to perform the site-directed
mutagenesis are described in Table 1. DNA sequencing used
the GeneReadir 4200 system (LiCor).
tTG expression and purification
Bacteria were grown in nutrient broth to OD600 ,0.5, induced
to express protein by addition of 1 mM IPTG (Sigma-Aldrich)
and grown overnight at room temperature with 200 rpm
agitation. The pelleted bacteria were resuspended in 20 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 15% glycerol
pH 8.0 and centrifuged at 3,5006g for 15 minutes. The
resulting pellets were stored at 280 C˚. For purification of
recombinant tTG, pellets were resuspended in 80 ml CelLytic
reagent (Sigma-Aldrich) containing 0.1 mg/ml lysozyme
(Sigma-Aldrich) and ,1,000 units DnaseI (Invitrogen). Lysate
was incubated at room temperature for 20 minutes and
homogenized by syringing. The lysate was then centrifuged at
25,0006g for 15 minutes to pellet insoluble material and the
resulting supernatant was incubated with 800 ml Glutathione
Sepharose slurry (Amersham). Sepharose was washed 64 in
phosphate buffered saline (PBS) and fusion protein was eluted
from the beads with elution solution (100 mM Glutathione,
20 mM Tris, pH 8.0). Recombinant tTG was stored in 50%
glycerol at 220 C˚. Protein batches were routinely checked for
purity by SDS–polyacrylamide gel electrophoresis (SDS–PAGE).
NanoOrangeTM assay for protein quantification
Protein yield was quantified using NanoOrangeTM reagent
(Molecular Probes). NanoOrangeTM is a fluorescent reagent
capable of detecting protein concentrations as low as 10 ng/ml,
offering a broad, dynamic quantification range and improved
sensitivity relative to absorption-based protein solution
assays.21 A standard curve was generated using bovine serum
albumin (BSA) ranging from 0.1 to 10 mg/ml in NanoOrange
reagent. Analytes were diluted in NanoOrange reagent and read
(lex 485, lem 595) in a Spectrafluor Plus instrument (Tecan).
Western blotting
SDS–PAGE was performed according to standard methods.
Protein was blotted onto polyvinylidene fluoride membranes
(Sigma-Aldrich) using a semi-dry apparatus (Apollo). The
membrane was blocked at 4 C˚ overnight with 5% non-fat dried
milk including 0.5% Tween 20 (Sigma-Aldrich). Primary
antibodies used were CUB7402/TG100, a monoclonal mouse
anti-tTG antibody (Labvision); GST01, a mouse anti-GST
antibody (Labvision); and polyclonal rabbit anti-tTG
(Roboscreen). All primary antibodies were diluted 1:1000 in
5% non-fat dried milk including 0.5% Tween. After incubation
for 2 h at room temperature and thorough washing with PBS
containing 0.1% Tween, the membranes were incubated with
1:1000 dilution of either rabbit anti-mouse conjugated to
horseradish peroxidase (HRP) or swine anti-rabbit conjugated
to HRP (Dako). Blots were visualised using chromogenic
substrate 3,39-diaminobenzidine (Sigma-Aldrich) and hydro-
gen peroxide (Sigma-Aldrich).
ELISAs
ELISAs were performed by coating certified 96-well MaxisorpH
plates (Nunc) with 0.3 mg per well of either purified recombi-
nant tTG or mutant tTG for 16 h at 4 C˚ in coating buffer
(50 mM Tris-HCL, 150 mM NaCl, 5 mM CaCl2, pH 7.5). Wells
were blocked with 1% BSA (Diamed) in PBS for 1 h and
washed four times with PBS plus 0.1% Tween between each
step. Antibodies used in Western blots were also used as
primary antibodies in ELISAs as a further quantitative control.
Antibodies were diluted as follows: CUB7402/TG100 and GST01
were diluted 1:1000 with PBS plus 0.1% Tween followed by
rabbit anti-mouse conjugated with HRP (Dako). Polyclonal
anti-tTG was diluted 1:1000 with PBS plus 0.1% Tween
followed by 1:1000 swine anti-rabbit conjugated with HRP
(Dako). For IgA assays, human sera were diluted 1:20 with PBS
plus 0.1% Tween followed by 1:1000 rabbit anti-human IgA
conjugated to HRP (Dako). For IgG assays, human sera were
diluted 1:500 with PBS plus 0.1% Tween followed by 1:500
rabbit anti-human IgG conjugated to HRP (Dako). All antibody
incubations were performed at room temperature for 1 h.
ELISAs were developed using 3,39,5,59-tetramethylbenzidine
liquid substrate system (Sigma-Aldrich) for 7 minutes at room
temperature. ELISAs were read at A450 in a Wallac Victor2
multilabel counter. Cut-off points were established by incubat-
ing 49 serum samples found to be negative for anti-tTG
responses with wild-type and mutant tTGs. Cut-off points were
calculated as mean +2 standard deviations.
Statistics
The Mann–Whitney U test and Wilcoxon ranked sums test were
used to compare reactivity to wild-type and mutant tTG
antigens.
Table 1 Primers used in site-directed mutagenesis
Primer Sequence (59 R 39)
C277A-F GTCAAGTATGGCCAGGCTTGGGTCTTCGCCG
C277A-R CGGCGAAGACCCAAGCCTGGCCATACTTGAC
H335A-F CGAGATGATCTGGAACTTCGCTTGCTGGGTGGAGTCGTG
H335A-R CACGACTCCACCCAGCAAGCGAAGTTCCAGATCATCTCG
D358A-F GCAGGCCCTGGCCCCAACGCCCC
D358A-R GGGGCGTTGGGGCCAGGGCCTGC
The substituted nucleotides are underlined.
F, forward primer
R, reverse primer
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Ethical approval
Ethical approval for this study was obtained from the joint
ethics committee of St James’s and Tallaght hospitals.
RESULTS
Cloning strategy, sequencing and mutagenesis
Recombinant tTG was expressed as a glutathione-S-transferase
(GST) fusion protein. The solubility-enhancing properties of the
GST tag have been reported to increase yields of difficult
proteins.22 DNA sequencing confirmed the sequence identity,
which was homologous with the nucleotide sequence pre-
viously characterized by Gentile (1991).23 The Quickchange
system (Stratagene) was used for site-directed mutagenesis on
the three amino acids of the catalytic triad of tTG (Cys277, His335
and Asp358). The three amino acids were replaced with alanine
resides to remove any catalytic or steric properties of the
catalytic triad.
Protein production and quantification
Conditions for protein production were optimised at 1 mM IPTG
overnight at room temperature. Cells were lysed using CelLytic
(Sigma-Aldrich), a detergent-based reagent that releases 95%
of soluble proteins from Escherichia coli. The purified proteins
were examined by SDS–PAGE and shown to be highly pure
(fig 1). Since protein yields were consistently low,
NanoOrangeTM (Molecular Probes), a highly sensitive protein
quantification reagent, was used to determine tTG concentra-
tions. Wild-type tTG had an average yield of 1.15 mg/l of
bacteria whereas mutant protein preparations yielded, on
average, 50% less enzyme then wild-type tTG preparations
(data not shown).
Wild-type and mutant tTG characterisation
Reactivity of commercially available antibodies to wild-type and
mutant tTG was examined by ELISA (fig 2a). To confirm that
equivalent amounts of both fusion proteins were binding ELISA
plates, a commercial mouse anti-GST antibody was included in
some ELISAs and was found to bind equally to wells coated
with both wild-type and mutant tTG. To confirm conforma-
tional integrity of both wild-type and mutant tTGs, commer-
cially available antibodies directed against tTG were included in
ELISAs. A mixture of two mouse monoclonal antibodies
directed against tTG (CUB7402 + TG100 Neomarkers) bound
mutant tTG with slightly decreased affinity but this finding did
not reach statistical significance (Mann–Whitney U test).
Rabbit polyclonal anti-tTG (Roboscreen) bound both mutant
and wild-type tTGs with equal affinity. All three commercial
antibodies reacted with wild-type and mutant tTGs in Western
blots (fig 2b).
Wild-type and mutant tTG recognition by coeliac sera
Coeliac disease serum IgA reactivity to wild-type tTG correlated
well with IgA anti-tTG results from the CelikeyH tTG ELISA
system (r = 0.804). However, coeliac disease serum IgA
reactivity to mutant tTG was dramatically reduced compared
with wild-type tTG (Fig 3a). In fact, although 88.16% of coeliac
disease sera were found to be positive in the wild-type antigen
assay, only 18.42% of sera exceeded the cut-off point when
tested for IgA reactivity to the mutant tTG. There was, on
average, a 79% reduction in IgA class autoantibody binding to
mutant tTG compared with wild-type tTG.
In IgG ELISAs, sera were used at a higher dilution than in
IgA assays and, as a result, AU values were lower. Coeliac
disease serum IgG bound wild-type tTG at significantly higher
levels than control sera (p,0.005, Student’s t-test).
Interestingly, IgG reactivity did not mirror the pattern observed
in IgA assays (Fig 3b) as there was no significant difference
between coeliac disease IgG recognition of wild-type or mutant
tTG (Wilcoxon signed ranks test).
Wild-type and mutant tTG recognition by dermatitis
herpetiformis sera
The IgA wild-type tTG ELISA successfully identified 6 of 10
dermatitis herpetiformis sera as anti-tTG positive (fig 3c). In a
similar pattern to the results with sera of patients with coeliac
disease, dermatitis herpetiformis serum IgA showed a drama-
tically reduced binding to mutant tTG. All samples tested for
IgA binding to mutant tTG bound the antigen at a level below
the threshold for positivity, with a mean percentage reduction
in binding of 58% compared with wild-type tTG. Once again,
IgG responses did not mirror IgA results. IgG antibodies
showed no difference in binding to wild-type or mutant tTGs
(Fig 3d).
DISCUSSION
Recent discoveries in the field of coeliac disease have assigned
an important role to tTG in the deamidation of gliadin
molecules resulting in strengthening of interactions between
DQ2 and gliadin.13 In the light of these discoveries, a role for the
autoimmune response directed against tTG in the pathogenesis
of coeliac disease seems more plausible. A previous study has
suggested that blockade of tTG by autoantibodies could be
responsible for inhibition of epithelial cell differentiation and
contribute to the mucosal lesion observed in coeliac disease.24 In
a recent study by Sblattero et al. (2002), truncated tTG
fragments were applied as antigen to ELISAs with coeliac
disease sera to map immunodominant epitopes. Their results
suggested that an important conformation-dependent epitope
was to be found within the region spanning amino acids 140 to
376.18 Interestingly, this region encompasses the three amino
acids of the catalytic triad of tTG (Cys277, His335 and Asp358).
Since this region of tTG is only revealed upon Ca2+ activation
and is a site of tTG–gliadin interaction, it represents a valid
target for autoantibody binding studies.
In this study, a full-length recombinant tTG and a mutant
variant lacking the catalytic triad were produced to investigate
autoantibody binding to this region of tTG while attempting to
maintain overall protein conformation. This is the first time
site-directed mutagenesis has been used to investigate tTG
epitopes. These results demonstrate that the IgA anti-tTG
response in coeliac disease sera is specifically targeted towards
the region of the enzyme responsible for its transamidation and
deamidation reactions. In fact, all coeliac disease sera showed a
profound reduction in IgA binding to mutant tTG compared
with wild-type tTG, with 79% of sera reacting positively to the
wild-type tTG having no reactivity to the mutant tTG. This
effect was not limited to antigen coated on ELISA plates
because pre-incubation of coeliac disease sera with wild-type
tTG in solution caused almost complete depletion of IgA anti-
tTG antibodies whereas pre-incubation of coeliac disease sera
with mutant tTG had little effect on anti-tTG levels (data not
shown).
In similar experiments investigating IgG anti-tTG antibodies,
there was no significant difference in reactivity to wild-type or
mutant tTGs. Although in the assay conditions employed, IgG
anti-tTG levels did not exceed the cut-off levels for positivity,
IgG anti-tTG binding was still significantly higher in coeliac
disease than control sera (p,0.005, Student’s t test). The IgG
anti-tTG ELISA has been shown to be less sensitive than the
IgA assay, with sensitivities as low as 13% being reported
previously.25
Although mutagenesis could have affected the folding of the
mutant tTG and hence, affected autoantibody binding to the
mutant tTG, there are three reasons this does not seem to be
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the case in these experiments. First, a polyclonal antibody
raised against recombinant human tTG bound wild-type and
mutant tTGs equally (fig 2a). Second, in silico mutation of the
amino acids of the catalytic triad using the three-dimensional
position-sensitive scoring matrix (3D-PSSM) program26 showed
no notable difference in secondary structure as a result of the
mutations. Third, unlike IgA responses, there was no significant
difference between IgG binding of wild-type and mutant tTGs
(fig 3).
These results suggest a difference in specificity between IgA
and IgG class anti-tTG responses in coeliac disease. The IgA
anti-tTG response is focused on the active region of the enzyme
whereas the IgG antibodies appear to recognise other sites on
the protein and are largely unaffected by mutation of the
catalytic triad. The targeting of the active core of tTG by IgA
antibodies suggests the possibility that these autoantibodies
may affect the enzyme’s function. Although it might be
expected that inhibition of such a multifunctional enzyme
may be associated with some systemic consequences, it is
possible that tTG inhibition occurs primarily in the gut and is
mediated by the mucosal immunoglobulin class, IgA. These
antibodies could, therefore, contribute to the local coeliac
disease lesion. Using phage antibody libraries, Marzari and
colleagues (2001) demonstrated that unlike those against
gliadin, IgA antibodies directed against tTG can be isolated
from intestinal libraries but not from peripheral blood
libraries.27 These results suggest that the anti-tTG response is
generated at a local level whereas anti-gliadin responses are
systemic.
Several studies have shown some level of inhibition of tTG by
coeliac disease autoantibodies.28 29 These studies did not
preincubate tTG with antibodies at 37 C˚, possible because of
the instability of tTG preparations. The observation that tTG is
capable of continuing its cross-linking function to some extent
even in the presence of autoantibodies is not surprising because
antibody–antigen interactions are non-covalent and reversi-
ble.30 Furthermore, because substrate is in excess in these
artificial systems and the enzyme–substrate affinity is highly
evolved, substrate is likely to compete well with autoantibodies
for interaction with the catalytic triad.
In experiments investigating IgA anti-tTG antibodies from
patients with dermatitis herpetiformis, 6 out of 10 samples
were found to react to wild-type tTG. This is in keeping with
reports that a lower proportion of sera from patients with
dermatitis herpetiformis show positive anti-tTG serology
compared with coeliac disease sera.16 IgA and IgG class anti-
tTG autoantibodies from dermatitis herpetiformis patients
reacted to wild-type and mutant tTGs in a similar fashion to
those from coeliac disease sera. Epidermal transglutaminase
has recently been identified as the predominant autoantigen in
dermatitis herpetiformis. It has been suggested that dermatitis
herpetiformis patients may produce populations of antibodies
that react with tTG only, epidermal transglutaminase only, and
cross-reactive antibodies that target epitopes common to both
enzymes.17 Results from this study suggest that IgA anti-tTG
antibodies in dermatitis herpetiformis are very similar to those
found in coeliac disease. It is possible that the autoimmune
response in this disorder is initiated in the gut against tTG with
subsequent intermolecular epitope spreading to epidermal
transglutaminase.
Whether the potential inhibition of tTG activity by auto-
antibodies has any significance in vivo is yet to be determined.
However, the blockade of enzyme activity by autoantibodies is
not unprecedented. In Wegener’s granulomatosis, inhibition of
proteinase 3 by autoantibodies has been described31, whereas in
autoimmune atrophic gastritis the inhibition of the H+, K+-
ATPase proton pump by parietal cell autoantibodies has been
well characterised.32 It is worth noting that although antibody-
mediated enzyme inhibition is thought to play a role in both of
these conditions, total blockade of enzyme activity is not
reported. The highly specific nature of IgA anti-tTG targeting
could have implications for the activity of tTG at a local level by
two possible mechanisms. First, tTG has been shown to have a
role in the wound healing process, and its blockade by IgA anti-
tTG could interfere with coeliac lesion repair.6 A second
possibility is the prevention of villous crypt-cell differentiation:
tTG is involved in the activation of TGF-b, a cytokine required
for maturation of crypt cells into enterocytes.33 It has been
shown that IgA from patients with coeliac disease can block the
differentiation of T84 intestinal crypt cells in vitro.24 Given the
prevalence of IgA deficiency in coeliac disease patients,34 it
seems unlikely that these autoantibodies are involved in coeliac
disease aetiology but perhaps contribute to failure to repair the
gut lesion.
The discovery that tTG may have a pivotal role in coeliac
disease pathogenesis has led to speculation about a role for the
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Figure 1 SDS–PAGE of wild-type
tTG (1) and mutant tTG (2). tTG is
approximately 77 kilodaltons (kDa)
and the GST fusion tag is 26 kDa;
therefore fusion protein is
,103 kDa. Mutant tTG yields were
generally lower than wild-type tTG
yields.
Figure 2 (a) ELISAs comparing commercial antibody binding to wild-type
(black bars) and mutant tTG (white bars). (b) Western blots of wild-type
and mutant tTG with commercially available antibodies GST01 (1),
CUB7402/TG100 (2) and polyclonal anti-tTG (3) are shown in the inset.
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anti-tTG autoantibody component of this multifactorial disease.
In this study, evidence for the highly specific targeting of the
active site of tTG by IgA autoantibodies has been discovered,
whereas IgG autoantibodies seem unaffected by mutagenesis of
this catalytic triad. These findings suggest that anti-tTG
autoantibodies of mucosal origin could, at least partly, inhibit
tTG activity. These results help further dissect the role of the
autoantibody response against tTG in coeliac disease. Future
work could involve the investigation of the inhibitory capacity
of coeliac disease IgA anti-tTG on the cross-linking function of
tTG.
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